|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology: COPD in India - Aging, population growth, and increased survival will drive a marked increase in prevalent cases of COPD over the next ten years
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 01-Apr-2011
Please click here for more information or to purchase this report at our partner store
Overview of COPD definition and a review of the epidemiology literature for India. This report provides in-depth analysis of patient populations, a 10-year prevalent forecast, and key patient segments in India. |
|
|
Epidemiology: COPD in China - Aging, population growth, and increased survival will drive a marked increase in prevalent cases of COPD over the next ten years
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 01-Apr-2011
Please click here for more information or to purchase this report at our partner store
Overview of COPD definition and a review of the epidemiology literature for China. This report provides in-depth analysis of patient populations, a 10-year prevalent forecast, and key patient segments in China. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines
Price: $15,200.00 (€11,901.13) ($18,240.00 (€14,281.35) Including VAT at 20%)
|
| Publication Date: 22-Dec-2010
Please click here for more information or to purchase this report at our partner store
Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 29-Apr-2010
Please click here for more information or to purchase this report at our partner store
This report discusses the market opportunity for respiratory antivirals in the seven major markets (7MM). It outlines patient and sales data, provides an analysis of marketed and pipeline drugs, and discusses opportunities and threats in this sector. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
Price: $800.00 (€626.38) ($960.00 (€751.65) Including VAT at 20%)
|
| Publication Date: 01-May-2009
Format: PDF Email
Pages: 35
Publisher: Koncept Analytics
In the present era, use of tobacco, polluted environment, poverty and aging population have become a major threat; all these factors account for a major cause of deaths by COPD. Market for COPD medication is growing with increasing prevalence rate worldwide and it has become the fourth leading cause of death. The number of people with COPD varies throughout world. Cape Town has the highest prevalence of COPD, while Hanover has the lowest prevalence. In United States, its prevalence is high and geographically, its prevalence in the Southern part of the country is highest and the Northeastern part has the lowest prevalence rate. With increasing rate of COPD patients, the economic cost is also increasing, which leads to the highest economic cost out of all the lung diseases in United States. Spiriva is the leading medication for the disease while rest of the medicines market is expected to decline in future with the effect of new developments and increasing competition. At present Advair has also a good hold in the market. Inhalers demand is high for COPD and there are few oral medicines available. The present report analyses worldwide COPD market with prevalence of the disease in major parts of the world. It talks about United States and Australian market for the medication of COPD and mortality and death rates. Economic cost is also an important segment of the report in which we have discussed US and Australian markets. There are many factors driving the industry which are discussed in growth drivers. In future trends we have discussed the projected market condition, which may help in forming strategies. The report also talks about the future outlook of the industry and its growth. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own